Adolescent polycystic ovary syndrome

Adolescent Medicine: State of the Art Reviews

Volumn 23, Issue 1, 2012, Pages 164-177

  Connor, Ellen Lancon ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTIDIABETIC AGENT; INSULIN; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADOLESCENT DEVELOPMENT; BODY MASS; DYSMENORRHEA; FEMALE; FEMALE INFERTILITY; GENETIC PREDISPOSITION; HUMAN; HYPERANDROGENISM; LIFESTYLE; METABOLIC SYNDROME X; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; PUBERTY; REVIEW; RISK FACTOR;

ADOLESCENT; ADOLESCENT DEVELOPMENT; ANDROGEN ANTAGONISTS; BODY MASS INDEX; CONTRACEPTIVES, ORAL; DIABETES MELLITUS, TYPE 2; DYSMENORRHEA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERANDROGENISM; HYPOGLYCEMIC AGENTS; INFERTILITY, FEMALE; INSULIN; LIFE STYLE; METABOLIC SYNDROME X; OBESITY; POLYCYSTIC OVARY SYNDROME; PUBERTY; RISK FACTORS;

EID: 84864104197     PISSN: 19344287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Rosenfield R. Clinical review: identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:787-796
2. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev. 1995;16:322-353
3. Rosenfield RL. Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1999;28:265-293
4. Driscoll DA. Polycystic ovary syndrome in adolescence. Ann NY Acad Sci. 2003;997:49-55
5. Lewy VD, Danadian K, Witchel SF, et al. Early metabolic abnormalities in adolescent girls with polycystic ovary syndrome. J Pediatr. 2001;138:38
6. Bekx MT, Connor EL, Allen DB. Characteristics of adolescents presenting to a multidisciplinary clinic for polycystic ovarian syndrome. J Pediatr Adolesc Gynecol. 2010;23:7-10
7. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2006;91:492-497
8. Hickey M, Sloboda DM, Atkinson HC, et al. The relationship between maternal and umbilical cord androgen levels and ovarian function in adolescence: a prospective cohort study. / Clin Endocrinol Metab. 2009;94:3714-3720
9. Goodarzi MO, Azziz R. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab. 2006;20(2):193-205
10. Diamanti-Kandarakis E, Papavassiliou AT, Kandarakis SA, et al. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab. 2007;18:280
11. Azziz R, Kashar-Miller MD. Family history as a risk factor for the polycystic ovary syndrome. / Pediatr Endocrinol Metab. 2000;13(Suppl 5):1303-1306
12. Yildiz BO, Yarali H, Oguz H, Bayraktar M. Glucose intolerance, insulin resistance, and hyperan-drogenemia in first degree relatives of women with polycystic ovary syndrome. / Clin Endocrinol Metab. 2003;88:2031-2036
13. Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev. 2005;26:251-282
14. Rosencratz MA, Coffler MS, Haggan A, et al. Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome. / Clin Endocrinol Metab. 2011;96:1106-1113
15. Urbanek M, Sam S, Legro RS, Dunaif A. Identification of a polycystic ovary syndrome susceptibility variant in fibrillin-3 and association with a metabolic phenotype. J Clin Endocrinol Metab. 2007;92:4191-4198
16. Ewens KG, Stewart DR, Ankener W, et al. Family-based analysis of candidate genes for polycystic ovary syndrome. J Clin Endocrinol Metab. 2010;95:2306-2315
17. Leibel NI, Baumann EE, Kocherginsky M, Rosenfield RL. Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome. / Clin Endocrinol Metab. 2006;91:1275-1283
18. Abbott DH, Tarantal AF, Dumesic DA. Fetal, infant, adolescent, and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys. Am J Primatol. 2009;71:776-784
19. Ibanez L, Potau N, Francois I, de Zegher F. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. / Clin Endocrinol Metab. 1998;83:3558-3662
20. Ibanez L, Vails C, Potau N, Marcos MV, de Zegher F. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. / Clin Endocrinol Metab. 2000;85(10):3526-3530
21. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: toward a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic Ovary Syndrome. Boston, MA: Blackwell Science Publications; 1992:377-384
22. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Human Reprod. 2004;19:41-47
23. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. / Clin Endocrinol Metab. 2006;91:4237-4245
24. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil SteriL 2009;91(2):456-488
25. Chen Y, Yang D, Li L, Chen X. The role of ovarian volume as a diagnostic criterion for Chinese adolescents with polycystic ovary syndrome. / Pediatr Adolesc Gynecol. 2008;21(6):347-350
26. Carmina E. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol. 2010;203(3):201.el-5
27. Vieira JG. The importance of methodology in serum testosterone measurement: comparison between a direct immunoassay and a method based on a high performance liquid chromatography and tandem mass spectroscopy. Arq Brs Endocrinol Metab. 2008;52(6):1050-1055
28. Legro RS, Finegood D, Danaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. / Clin Endocrinol Metab. 1998;83:2694-2698
29. Vuguin P, Saenger P, diMartino-Nardi J. Fasting glucose insulin ratio: a useful measure of insulin resistance in girls with premature adrenarche. / Clin Endocrinol Metab. 2001;86:4618-4621
30. Berlan ED, Emans SJ. Managing polycystic ovarian syndrome in adolescent patients. J Pediatr Adolesc Gynecol. 2009;22:137-140
31. Parkin L, Sharpies K, Hernandez RK, Jick SS. Risk of thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested, case-control study based on UK General Practice Research Database. BrMed J. 2011 ;342:d2139
32. Dunn N. The risk of deep venous thrombosis with oral contraceptives containing drospirenone. BMJ. 201 l;342:d2519
33. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440
34. Malhotra B, Noveck R, Behr D, Palmisano M. Percutaneous absorption and pharmacokinetics of Eflornithine Hd 13.9% cream in women with unwanted facial hair. / Clin Pharmacol. 2001;41:972-978
35. Yasar L, Ekin M, Gedikbasi A, Erturk AD, Savan K, Ozdemir A, Temur M. Serum adiponectin levels in high school girls with polycystic ovary syndrome and hyperandrogenism. / Pediatr Adolesc Gynecol. 2011;24:85-89
36. Hoeger KM. Role of lifestyle modification in the management of polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab. 2006;20:293
37. Wabitsch M, Hauner H, Heinze E, et al Body fat distribution and steroid hormone concentrations in obese adolescent girls before and after weight reduction. J Clin Endocrinol Metab. 1995;80:3469
38. Ornstein RM, Copperman NM, Jacobson MS. Effect of weight loss on menstrual function in adolescents with polycystic ovary syndrome. / Pediatr Adolesc Gynecol. 2011;24:161-165
39. Allen HF. Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. / Pediatr Endocrinol Metab. 2005; 18(8):761-768
40. Trent ME, Rich M, Austin SB, et aL Quality of life in adolescent girls with polycystic ovary syndrome. Arch Pediatr Adolesc Med. 2002;156:556
41. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. / Am Coll Cardiol. 2008;52:686-717
42. Tasali E, Ip MS. Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation. ProcAm Thorac Soc. 2008;5:207-217
43. Fogel RB, Malhotra A, Pillar G, Pittman SD, Dunaif A, White DP. Increased prevalence of obstructive sleep apnea in obese women with polycystic ovary syndrome. / Clin Endocrinol Metab. 2001;86:1175-1180
44. Tasali E, Chapotot F, Leproult R, Whitmore H, Ehrmann DA. Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. / Clin Endocrinol Metab. 2011;96(2):365-374
45. Ma RCW, Liu KH, Lam PM et al. Sonographic measurement of mesenteric fat predicts presence of fatty liver among subjects with polycystic ovary syndrome. / Clin Endocrinol Metab. 2011;96(3):799-807
46. Setji TL, Holland ND, Sanders LL, et al. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. ] Clin Endocrinol Metab. 2006:91:1741
47. Reeder SB, Robson PM, Yu H, et al. Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling. MagReson Imaging. 2009;29(6):1332-1339
48. Rehm JL, Connor EL, Reeder SB. Nonalcoholic fatty liver disease in an adolescent with polycystic ovarian syndrome. J. Pediatr Adolesc Gynecol. 2011 ;24(2):e61 [Abstract]
49. Reisen E. Obesity and hypertension: mechanisms, cardio-renal consequences, and therapeutic approaches. Med Clin North Am. 2009;93(3):733-751